Literature DB >> 8540733

Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus.

W S Champney1, R Burdine.   

Abstract

Macrolide antibiotics are clinically important antibiotics which are effective inhibitors of protein biosynthesis in bacterial cells. We have recently shown that some of these compounds also inhibit 50S ribosomal subunit formation in Escherichia coli. Now we show that certain macrolides have the same effect in two gram-positive organisms, Bacillus subtilis and Staphylococcus aureus. Assembly in B. subtilis was prevented by erythromycin, clarithromycin, and azithromycin but not by oleandomycin. 50S subunit formation in S. aureus was prevented by each of seven structurally related 14-membered macrolides but not by lincomycin or two streptogramin antibiotics. Erythromycin treatment did not stimulate the breakdown of performed 50S subunits in either organism. The formation of the 30S ribosomal subunit was also unaffected by these compounds. Assembly was also inhibited in a B. subtilis strain carrying a plasmid with the ermC gene that confers macrolide resistance by rRNA methylation. These results suggest that ribosomes contain an additional site for the inhibitory functions of macrolide antibiotics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8540733      PMCID: PMC162898          DOI: 10.1128/AAC.39.9.2141

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Lack of complete cooperativity of ribosome assembly in vitro and its possible relevance to in vivo ribosome assembly and the regulation of ribosomal gene expression.

Authors:  J Dodd; J M Kolb; M Nomura
Journal:  Biochimie       Date:  1991-06       Impact factor: 4.079

2.  Action of antibiotics on chain-initiating and on chain-elongating ribosomes.

Authors:  P C Tai; B D Davis
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

3.  Some effects of antibiotics on bacterial polyribosomes as studied by gel electrophoresis.

Authors:  A E Dahlberg; E Lund; N O Kjeldgaard
Journal:  J Mol Biol       Date:  1973-08-25       Impact factor: 5.469

4.  Correlation between the peptidyl transferase activity of the 50 s ribosomal subunit and the ability of the subunit to interact with antibiotics.

Authors:  Z Vogel; T Vogel; A Zamir; D Elson
Journal:  J Mol Biol       Date:  1971-09-14       Impact factor: 5.469

5.  Two types of binding of erythromycin to ribosomes from antibiotic-sensitive and -resistant Bacillus subtilis 168.

Authors:  N L Oleinick; J W Corcoran
Journal:  J Biol Chem       Date:  1969-02-25       Impact factor: 5.157

6.  The intermolecular complex of erythromycin and ribosome.

Authors:  J C Mao; M Putterman
Journal:  J Mol Biol       Date:  1969-09-14       Impact factor: 5.469

7.  Nucleotide sequence and functional map of pE194, a plasmid that specifies inducible resistance to macrolide, lincosamide, and streptogramin type B antibodies.

Authors:  S Horinouchi; B Weisblum
Journal:  J Bacteriol       Date:  1982-05       Impact factor: 3.490

8.  Plasmid copy number control: isolation and characterization of high-copy-number mutants of plasmid pE194.

Authors:  B Weisblum; M Y Graham; T Gryczan; D Dubnau
Journal:  J Bacteriol       Date:  1979-01       Impact factor: 3.490

9.  Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics.

Authors:  R Skinner; E Cundliffe; F J Schmidt
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

10.  Construction and properties of chimeric plasmids in Bacillus subtilis.

Authors:  T J Gryczan; D Dubnau
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

View more
  16 in total

Review 1.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Macrolide myths.

Authors:  Alexander S Mankin
Journal:  Curr Opin Microbiol       Date:  2008-10-03       Impact factor: 7.934

3.  50S ribosomal subunit synthesis and translation are equivalent targets for erythromycin inhibition in Staphylococcus aureus.

Authors:  W S Champney; R Burdine
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Hygromycin B inhibition of protein synthesis and ribosome biogenesis in Escherichia coli.

Authors:  Susan M McGaha; W Scott Champney
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

5.  Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells.

Authors:  W S Champney; C L Tober
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Quantitative proteomic analysis of ribosome assembly and turnover in vivo.

Authors:  Michael T Sykes; Zahra Shajani; Edit Sperling; Andrea H Beck; James R Williamson
Journal:  J Mol Biol       Date:  2010-08-13       Impact factor: 5.469

7.  Evernimicin (SCH27899) inhibits both translation and 50S ribosomal subunit formation in Staphylococcus aureus cells.

Authors:  W S Champney; C L Tober
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  YsxC, an essential protein in Staphylococcus aureus crucial for ribosome assembly/stability.

Authors:  Elizabeth L Cooper; Jorge García-Lara; Simon J Foster
Journal:  BMC Microbiol       Date:  2009-12-18       Impact factor: 3.605

9.  Erythromycin- and chloramphenicol-induced ribosomal assembly defects are secondary effects of protein synthesis inhibition.

Authors:  Triinu Siibak; Lauri Peil; Liqun Xiong; Alexander Mankin; Jaanus Remme; Tanel Tenson
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

10.  Erythromycin resistance by L4/L22 mutations and resistance masking by drug efflux pump deficiency.

Authors:  Martin Lovmar; Karin Nilsson; Eliisa Lukk; Vladimir Vimberg; Tanel Tenson; Måns Ehrenberg
Journal:  EMBO J       Date:  2009-02-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.